Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
2010

CD133 and Its Role in Endometrial Cancer

Sample size: 12 publication 10 minutes Evidence: moderate

Author Information

Author(s): Friel Anne M, Zhang Ling, Curley Michael D, Therrien Vanessa A, Sergent Petra A, Belden Sarah E, Borger Darrell R, Mohapatra Gayatry, Zukerberg Lawrence R, Foster Rosemary, Rueda Bo R

Primary Institution: Massachusetts General Hospital

Hypothesis

CD133 expression in endometrial cancer may be epigenetically regulated and contribute to tumorigenicity.

Conclusion

CD133 expression in endometrial cancer is regulated by methylation and is associated with increased tumorigenicity.

Supporting Evidence

  • CD133+ cells were confirmed to have tumor initiating potential in NOD/SCID mice.
  • The percentage of CD133+ cells in tumors increased with serial transplantation.
  • CD133 promoter methylation was found to decrease in malignant endometrial tissue compared to benign tissue.
  • Treatment with a demethylating agent increased CD133 expression in endometrial cancer cell lines.

Takeaway

This study found that a specific marker called CD133 helps identify cancer cells that can start new tumors in endometrial cancer, and its levels can change due to chemical modifications in the DNA.

Methodology

The study used flow cytometry to assess CD133 expression and analyzed tumorigenicity in NOD/SCID mice.

Potential Biases

Potential bias in sample selection and processing methods.

Limitations

The samples were not linked to clinical information due to IRB protocol.

Participant Demographics

Human endometrial tumor samples from women undergoing surgery.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/1477-7827-8-147

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication